Abstract
CYCLOSPORIN A and the newly discovered immunosuppressant, FK-506, are potent inhibitors of T cell activation1. In addition to their clinical importance in the prevention of allograft rejection, cyclosporin A and FK-506 represent important reagents for the study of the molecular mechanisms of lymphocyte activation. Cyclosporin A, a cyclic undecapeptide and FK-506, a macrolide, although chemically distinct, inhibit similar lymphocyte activation responses1, 2. The earliest responses inhibited in the T cell seem to be the expression of early phase T cell-activation genes for inter-leu kins 2, 3 and 4, granulocyte-macrophage colony stimulating factor and gamma interferon2–4. Although FK-506 and cyclosporin A seem to inhibit similar signal transduction processes, they do so by interacting with distinct cytosolic proteins5, 6. We report here the purification to homogeneity of a specific FK-506 binding protein that is distinct from the cyclosporin A-binding protein, cyclophilin7, 8. In addition, we show that this FK-506 binding protein, like cyclophilin, has peptidyl-prolyl isomerase activity9, 10.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sawada, S., Suzuki, G., Kawase, Y. & Takaku, F. J. Immun. 139, 1797–1803 (1987).
Tocci, M. J. et al. J. Immun. 143, 718–726 (1989).
Kronke, M. et al. Proc. natn. Acad. Sci. USA. 81, 5214–5218 (1984).
Elliott, J. F. et al. Science 226, 1439–1441 (1984).
Warty, V. et al. Transplantation 46, 453–455 (1988).
Siekierka, J. J., Staruch, M. J., Hung, S. H. Y. & Sigal, N. H. J. Immun. 143, 158–1583 (1989).
Handschumacher, R. E., Harding, M. W., Rice, J., Drugge, R. J. & Speicher, D. W. Science 226, 544–547 (1984).
Harding, M. W. & Handschumacher, R. E. Transplantation 46, 29S–35S (1988).
Takahashi, N., Hagano, T. & Suzuki, M. Nature 337, 473–475 (1989).
Fischer, G., Wittmann-Liebold, B., Lang, K., Kiethaber, T. & Schmidt, F. X. Nature 337, 476–478 (1989).
Harding, M. W., Handschumacher, R. E. & Speicher, D. W. J. biol. Chem. 261, 8547–8555 (1986).
Bradford, M. M. Analyt. Blochem. 72, 248–254 (1976).
Munson, P. J. & Rodbard, D. Analyt. Biochem. 107, 220–239 (1980).
Brandl, C. L. & Deber, C. M. Proc. natn. Acad. Sci. U.S.A. 83, 917–921 (1986).
Shieh, B-H., Stamnes, M. A., Seavello, S., Harris, G. L. & Zuker, C. S. Nature 338, 67–70 (1989).
Lin, C. S. et al. J. Immun. (submitted).
Wicker, L. et al. J. Immun. (submitted).
June, C. H., Ledbetter, J. A., Gillespie, M. M., Lindsten, T. & Thompson, C. B. Molec. cell. Biol. 7, 4472–4481 (1987).
Haendler, B., Hofer-Warbinek, R. & Hofer, E. EMBO J. 6, 947–950 (1987).
Danielson, P. E. et al. DNA 7, 261–267 (1988).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Siekierka, J., Hung, S., Poe, M. et al. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 341, 755–757 (1989). https://doi.org/10.1038/341755a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/341755a0
This article is cited by
-
Characterization and regulation of salt upregulated cyclophilin from a halotolerant strain of Penicillium oxalicum
Scientific Reports (2023)
-
Impact of distant peptide substrate residues on enzymatic activity of SlyD
Cellular and Molecular Life Sciences (2022)
-
Genome-wide characterization of peptidyl-prolyl cis–trans isomerases in Penicillium and their regulation by salt stress in a halotolerant P. oxalicum
Scientific Reports (2021)
-
Tacrolimus Decreases Cognitive Function by Impairing Hippocampal Synaptic Balance: a Possible Role of Klotho
Molecular Neurobiology (2021)
-
Effects of red blood cell concentrate transfusion on blood tacrolimus concentration
International Journal of Clinical Pharmacy (2020)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.